This inventor holds 5 USPTO granted patents. Top assignee: Bristol-Myers Company. Active years: 1982-1988.
Company Filing History:
Years Active: 1982-1988
Title: Fumihide Sakai: Innovator in Antibacterial and Antitumor Research
Introduction
Fumihide Sakai is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of microbiology and pharmaceuticals, particularly in the development of antibacterial and antitumor agents. With a total of five patents to his name, Sakai's work has had a profound impact on medical research and treatment options.
Latest Patents
Sakai's latest patents include the development of a microorganism for BBM 928 production. The actinomycete 'Actinomadura sp.' designated in his culture collection as Strain No. G455-101 has been deposited with the American Type Culture Collection under the Accession Number ATCC No. 31491. The taxonomic description of this microorganism is presented in detail in the specification, along with instructions for fermenting aqueous nutrient media to produce the BBM 928 antibiotic complex. This complex has demonstrated utility as an antibacterial agent against gram-positive and acid-fast bacteria and exhibits antitumor activity against experimental animal tumors. Another significant patent involves the fermentation process for BBM-928, which is a mixture of antitumor antibacterial substances produced by the fermentation of Actinomadura sp., ATCC No. 31491, under controlled conditions.
Career Highlights
Sakai is currently associated with Bristol-Myers Company, where he continues to innovate and contribute to the field of pharmaceuticals. His work has been instrumental in advancing the understanding and application of microbial agents in medicine.
Collaborations
Sakai has collaborated with notable coworkers, including Hideo Koshiyama and Hiroaki Ohkuma, to further enhance the research and development of his patented technologies.
Conclusion
Fumihide Sakai's contributions to the field of microbiology and pharmaceuticals are noteworthy. His innovative work in developing antibacterial and antitumor agents has the potential to significantly impact medical treatments. His ongoing research continues to pave the way for advancements in healthcare.